Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy

Ospemifene—a third-generation selective estrogen receptor modulator approved by the Food and Drug Administration in 2013—is an oral medication for the treatment of dyspareunia. In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vag...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Jae Jun, Kim, Seul Ki, Lee, Jung Ryeol, Suh, Chang Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Menopause 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606913/
https://www.ncbi.nlm.nih.gov/pubmed/28951854
http://dx.doi.org/10.6118/jmm.2017.23.2.79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606913/
https://www.ncbi.nlm.nih.gov/pubmed/28951854
http://dx.doi.org/10.6118/jmm.2017.23.2.79

Ejemplares similares